Verismo Therapeutics has commenced the first patient dosing in its multicentre Phase I CELESTIAL-301 trial of SynKIR-310.

There are over 300 glucagon-like peptide-1 receptor (GLP-1R) drugs in an active stage of development as the astounding success of Novo Nordisk’s GLP-1R obesity drug, Wegovy, has ignited a surge in ...

There is a significant discourse in the literature when estimating clinical trial costs due to the lack of transparency throughout the industry regarding the true expense of bringing a drug from bench ...

Pfizer's Phase III trial of sasanlimab with BCG in subjects with BCG-naïve, high-risk NMIBC, has met its primary endpoint.

The Phase Ia trial is designed to assess the company’s drug designed to target chemicals thought to be a cause of Alzheimer’s disease.

HMNC has completed the subject randomisation in its Phase IIb OLIVE trial of BH-200 for major depressive disorder (MDD) treatment.

Alentis Therapeutics has reported positive topline outcomes from two clinical trials of lixudebart (ALE.F02) for reversing organ fibrosis.

The announcement follows just days after the US Centres for Disease Control confirmed its first death from Avian Influenza.

IO Biotech has finished enrolling subjects in a Phase II trial of IO102-IO103 in conjunction with MSD's KEYTRUDA (pembrolizumab).

The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...

ISM5411 was well tolerated and demonstrated a favourable pharmokinetic profile in validating gut-restrictive properties.

The company says the early trial of its hair-loss therapy saw patients benefit from six times more hair growth than placebo.